Volume | 10,716,684 |
|
|||||
News | - | ||||||
Day High | 1.19 | Low High |
|||||
Day Low | 0.92 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Sunshine Biopharma Inc | SBFM | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.19 | 0.92 | 1.19 | 0.93 | 1.21 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
36,431 | 10,716,684 | $ 1.03 | $ 11,002,660 | - | 0.92 - 140.00 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:59:59 | 10 | $ 0.9289 | USD |
Sunshine Biopharma Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
23.62M | 25.68M | - | 24.09M | -4.51M | -0.18 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Sunshine Biopharma News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SBFM Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 3.57 | 6.80 | 0.92 | 2.03 | 6,338,742 | -2.65 | -74.23% |
1 Month | 5.61 | 13.25 | 0.92 | 9.22 | 29,416,117 | -4.69 | -83.60% |
3 Months | 23.90 | 28.56 | 0.92 | 8.28 | 25,976,762 | -22.98 | -96.15% |
6 Months | 31.46 | 32.98 | 0.92 | 8.41 | 12,136,536 | -30.54 | -97.08% |
1 Year | 70.00 | 140.00 | 0.92 | 12.57 | 6,440,956 | -69.08 | -98.69% |
3 Years | 275.00 | 987.00 | 0.92 | 175.80 | 4,494,028 | -274.08 | -99.67% |
5 Years | 275.00 | 987.00 | 0.92 | 175.80 | 4,494,028 | -274.08 | -99.67% |
Sunshine Biopharma Description
Sunshine Biopharma Inc is a pharmaceutical company focused on the research, development, and commercialization of oncology and antiviral drugs. In addition, it is engaged in the development and commercialization of science-based nutritional supplements. The company is focusing on the development of the licensed Adva-27a anticancer drug, a small molecule that has been shown to be exceptionally effective at destroying Multidrug-Resistant Cancer Cells, including Pancreatic Cancer cells (Panc-1), Small-Cell Lung Cancer cells (H69AR), Breast Cancer cells (MCF-7/MDR) and Uterine Sarcoma cells (MES-SA/Dx5). |